Chemomab Therapeutics (NASDAQ:CMMB) Stock Price Up 4.7% – Here’s What Happened

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB)’s share price rose 4.7% during trading on Thursday . The company traded as high as $1.84 and last traded at $1.80. Approximately 31,693 shares traded hands during mid-day trading, a decline of 35% from the average daily volume of 48,497 shares. The stock had previously closed at $1.72.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Chemomab Therapeutics in a report on Friday, May 8th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Chemomab Therapeutics has an average rating of “Hold” and a consensus target price of $25.00.

Chemomab Therapeutics Price Performance

The firm has a market capitalization of $12.94 million, a P/E ratio of -0.81 and a beta of 0.62. The stock’s fifty day simple moving average is $1.70 and its 200 day simple moving average is $1.84.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.18). As a group, sell-side analysts forecast that Chemomab Therapeutics Ltd. Sponsored ADR will post -0.4 EPS for the current fiscal year.

Hedge Funds Weigh In On Chemomab Therapeutics

Several hedge funds have recently modified their holdings of CMMB. ADAR1 Capital Management LLC acquired a new position in shares of Chemomab Therapeutics during the fourth quarter valued at about $132,000. Kestra Private Wealth Services LLC acquired a new position in shares of Chemomab Therapeutics during the fourth quarter valued at about $85,000. Finally, XTX Topco Ltd acquired a new position in shares of Chemomab Therapeutics during the fourth quarter valued at about $31,000. Institutional investors and hedge funds own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.